Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation.

Acta neuropathologica communications - 4 Nov 2022

Lakis Nelli S, Brodsky Alexander S, Karashchuk Galina, Audesse Amanda J, Yang Dongfang, Sturtevant Ashlee, Lombardo Kara, Wong Ian Y, Webb Ashley E, Anthony Douglas C

Abstract excerpt

A growing body of evidence supports the presence of a population of cells in glioblastoma (GBM) with a stem cell-like phenotype which shares certain biological markers with adult neural stem cells, including expression of SOX2, CD133 (PROM1), and NES (nestin). This study was designed to determine the relationship between the expression of these stem cell markers and the clinical outcome in GBM patients. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Stem Cells

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36333778
DOI: 10.1186/s40478-022-01459-9
PMCID: PMC9636755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation.PMID 36333778Read ↗

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapySemantic proximity Read ↗

An Epigenetic Biomarker Panel for Glioblastoma Multiforme Personalized Medicine through DNA Methylation Analysis of Human Embryonic Stem Cell-like SignatureSemantic proximity Read ↗

Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cellsSemantic proximity Read ↗

Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations.Semantic proximity Read ↗

Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastomaSemantic proximity Read ↗

O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting ConditionsSemantic proximity Read ↗

Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomasSemantic proximity Read ↗

A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutationsSemantic proximity Read ↗

Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas.Semantic proximity Read ↗

Cancer Stem Cells in Glioblastoma MultiformeSemantic proximity Read ↗

Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiformeSemantic proximity Read ↗

Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of OriginSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.